Kalmanti, L
Saussele, S
Lauseker, M
Müller, M C
Dietz, C T
Heinrich, L
Hanfstein, B
Proetel, U
Fabarius, A
Krause, S W
Rinaldetti, S
Dengler, J
Falge, C
Oppliger-Leibundgut, E
Burchert, A
Neubauer, A
Kanz, L
Stegelmann, F
Pfreundschuh, M
Spiekermann, K
Scheid, C
Pfirrmann, M
Hochhaus, A
Hasford, J
Hehlmann, R
,
Article History
Received: 23 September 2014
Revised: 15 December 2014
Accepted: 6 February 2015
First Online: 13 February 2015
Competing interests
: SS has received honoraria from Novartis, Bristol-Myers Squibb (BMS), Pfizer and research funding from Novartis and BMS; MCM honoraria and research funding from Novartis, BMS, ARIAD and Pfizer; BH honoraria from BMS and research funding from Novartis; AN honoraria from Medupdate; CS honoraria for consulting from Novartis; MP honoraria from BMS and consultancy from Novartis; AH honoraria from Novartis, BMS,ARIAD, consultancy from Novartis and research funding from Novartis, ARIAD and Pfizer and RH has research funding from Novartis and BMS. The remaining authors declare no conflicts of interest.